Intellia Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $67.7M | $57.9M | $36.3M | $52.1M | $33.1M |
| Cost of revenue | — | — | — | — | $0 |
| Research and development | $388.9M | $466.3M | $435.1M | $420.0M | $229.8M |
| Operating income | -$441.0M | -$534.3M | -$515.3M | -$458.2M | -$267.9M |
| Income tax expense | $0 | — | — | — | — |
| Net income | -$412.7M | -$519.0M | -$481.2M | -$474.2M | -$267.9M |
| Balance Sheet | |||||
| Cash and equivalents | $155.5M | $189.2M | $226.7M | $523.5M | $123.4M |
| Current assets | $527.7M | $639.9M | $998.3M | $1.2B | $769.3M |
| Total assets | $842.1M | $1.2B | $1.3B | $1.5B | $1.3B |
| Current liabilities | $103.9M | $110.9M | $115.2M | $126.6M | $125.8M |
| Total liabilities | $170.7M | $319.1M | $250.8M | $284.5M | — |
| Stockholders' equity | $671.4M | $872.0M | $1.1B | $1.2B | $1.0B |
| Cash Flow Statement | |||||
| Cash from operations | -$394.7M | -$348.9M | -$394.1M | -$333.3M | -$225.0M |
| Depreciation and amortization | $9.8M | $10.3M | $9.0M | $7.6M | $6.9M |
| Stock-based compensation | $80.2M | $154.3M | $134.1M | $91.4M | $47.0M |
| Capital expenditure | $1.1M | $5.8M | $14.0M | $13.6M | $12.8M |
| Free cash flow | -$395.9M | -$354.7M | -$408.1M | -$346.8M | -$237.8M |
Shares outstanding 139.7M · Free float 93.9%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.